Business
Easton Pharmaceuticals and BMV Medica Finalize License Agreement With CommonSense Ltd. of Israel to Be Sole Distributor for Patented AL-Sense (Amnio-Sense-Blue) Amniotic Fluid Leak Test for Latin America
Easton Pharmaceuticals and BMV Medica Finalize License Agreement With CommonSense Ltd. of Israel to Be Sole Distributor for Patented AL-Sense (Amnio-Sense-Blue) Amniotic Fluid Leak Test for Latin America.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals and BMV Medica Finalize License Agreement With CommonSense Ltd. of Israel to Be Sole Distributor for Patented AL-Sense (Amnio-Sense-Blue) Amniotic Fluid Leak Test for Latin America\n \n \nEaston Pharmaceuticals and BMV Medica Finalize License Agreement With CommonSense Ltd. of Israel to Be Sole Distributor for Patented AL-Sense (Amnio-Sense-Blue) Amniotic Fluid Leak Test for Latin America\n\nRevenue Projections Could Dwarf Britain's Expected $10 Million per Year Due to Many Times Higher Birth Rates in Latin America\n\n \n TORONTO, ON--(Marketwired - Aug 4, 2015) -  Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces Easton and BMV have signed an agreement and made a payment to Common Sense LTD. of Israel for the exclusive rights to market and sell Common Sense's AL-Sense (Amniotic-Sense-Blue) Amniotic Fluid Leak Test for most of Latin America.\n This Amniotic fluid test is intended for pregnant women, mainly in late-stage pregnancy, to enable them to detect the difference between an amniotic fluid leak which would necessitate a doctor's visit (as labour has started) and a simple urine leak. The test may also be used by High Risk pregnant women to monitor for Amniotic Fluid leaks beginning at earlier stages of pregnancy. This test is a state-of the art diagnostic test which is in the form of a panty liner, and undergoes a simple color change if the wetness experienced by the pregnant woman is caused by an amniotic fluid leak. The relatively low cost and ease of use is expected to quickly become the test of choice for both women at home and in hospital use.\n This test has been endorsed by NHS (National Health Service) in Britain as part of the NICE report (National Institute for Health and Care Excellence), which indicates that the device can reliably exclude amniotic fluid leak as a cause of vaginal wetness in pregnancy, avoiding the need for a speculum examination and its associated discomforts. Using the device in the community could prevent unnecessary referrals to secondary care antenatal day units or maternity triage services for speculum examinations, releasing clinical time. Based on cost modeling, using the test offers significant cost savings.\n  Other countries where the AL-Sense test is being sold include UK, Italy, Japan, China, Israel, Australia and other countries. The p...